Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2026)

Barinthus Biotherapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $92.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 35.11% year-over-year to $92.1 million; the trailing twelve-month figure through Mar 2026 stood at $429.1 million (down 36.69% YoY), and the FY2025 full-year result was $98.2 million, down 38.77% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $92.1 million, down from $98.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $286.1 million in Q1 2022, with the low at $92.1 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $198.6 million across 5 years, with a median of $199.5 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 71.85% — and 2025, when it plunged 42.13%.
• Barinthus Biotherapeutics' Liabilities and Shareholders Equity stood at $270.2 million in 2022, then retreated by 20.61% to $214.5 million in 2023, then retreated by 25.26% to $160.3 million in 2024, then sank by 38.77% to $98.2 million in 2025, then declined by 6.14% to $92.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $92.1 million (Q1 2026), $98.2 million (Q4 2025), and $109.2 million (Q3 2025), per Business Quant data.